TY - JOUR
T1 - Eicosapentaenoic acid ethyl ester supplementation in cachectic cancer patients and healthy subjects: effects on lipolysis and lipid oxidation
AU - van Zuijdgeest Leeuwen, S.D.
AU - Dagnelie, P.C.
AU - Wattimena, J.D.L.
AU - van den Berg, J.W.O.
AU - van der Gaast, A.
AU - Swart, G.R.
AU - Wilson, J.H.P.
PY - 2000/1/1
Y1 - 2000/1/1
N2 - Background & aims: Recent reports suggest that weight loss in cachectic cancer patients may be inhibited by supplementation of the n-3 fatty acid eicosapentaenoic acid (20.5n-3, EPA), presumably due to inhibition of lipolysis. The aim of the present double-blind, randomized trial was to assess whether short-term oral EPA ethyl ester (EE) supplementation inhibits lipolysis and lipid oxidation in weight-losing cancer patients and in healthy subjects. Methods: Seventeen weight losing, cancer patients of different tumor types, and 16 healthy subjects were randomized to receive EPA-EE (6 g/d) or placebo (oleic acid (OA)-EE; 6 g/d) for seven days. At baseline (day 0) and during supplementation (days 2 and 7) whole-body lipolysis and palmitic acid release were measured in the overnight fasting state using [1, 1, 2, 3, 3-H-2(5)] glycerol and [1-C-13] palmitic acid. Palmitate oxidation was determined by measuring (CO2)-C-13 enrichment in expired breath. Results: No significant effects of EPA-EE on whole-body lipolysis, palmitic acid release, or palmitate oxidation were detected in cancer patients nor in healthy subjects in comparison with OA-EE. EPA-EE supplementation reduced plasma-free fatty acid and triacylglycerol concentrations significantly in healthy subjects bur not in cancer patients. Conclusion: We conclude that supplementation of EPA-EE does not significantly inhibit lipolysis or lipid oxidation in weight-losing cancer patients or in healthy subjects during short-term supplementation when using OA-EE as a placebo supplement.
AB - Background & aims: Recent reports suggest that weight loss in cachectic cancer patients may be inhibited by supplementation of the n-3 fatty acid eicosapentaenoic acid (20.5n-3, EPA), presumably due to inhibition of lipolysis. The aim of the present double-blind, randomized trial was to assess whether short-term oral EPA ethyl ester (EE) supplementation inhibits lipolysis and lipid oxidation in weight-losing cancer patients and in healthy subjects. Methods: Seventeen weight losing, cancer patients of different tumor types, and 16 healthy subjects were randomized to receive EPA-EE (6 g/d) or placebo (oleic acid (OA)-EE; 6 g/d) for seven days. At baseline (day 0) and during supplementation (days 2 and 7) whole-body lipolysis and palmitic acid release were measured in the overnight fasting state using [1, 1, 2, 3, 3-H-2(5)] glycerol and [1-C-13] palmitic acid. Palmitate oxidation was determined by measuring (CO2)-C-13 enrichment in expired breath. Results: No significant effects of EPA-EE on whole-body lipolysis, palmitic acid release, or palmitate oxidation were detected in cancer patients nor in healthy subjects in comparison with OA-EE. EPA-EE supplementation reduced plasma-free fatty acid and triacylglycerol concentrations significantly in healthy subjects bur not in cancer patients. Conclusion: We conclude that supplementation of EPA-EE does not significantly inhibit lipolysis or lipid oxidation in weight-losing cancer patients or in healthy subjects during short-term supplementation when using OA-EE as a placebo supplement.
U2 - 10.1054/clnu.2000.0162
DO - 10.1054/clnu.2000.0162
M3 - Article
C2 - 11104593
SN - 0261-5614
VL - 19
SP - 417
EP - 423
JO - Clinical Nutrition
JF - Clinical Nutrition
ER -